{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:49:14Z","timestamp":1772070554521,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Patients with a prior history of cancer are commonly excluded from clinical trial. Increasing number of studies implied that a prior cancer did not adversely affect the clinical outcome among various types of cancer patients. However, the impact of prior cancer on survival of larynx cancer patients remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with larynx cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients with larynx cancer as the first or second primary malignancy diagnosed from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 24,812 eligible patients with larynx cancer were included in the study, wherein a total of 2436 patients (9.8%) had a prior history of cancer. Prostate (36%), lung and bronchus (10%), urinary bladder (7%), and breast (6%) were the most common types of prior cancer. A prior cancer history served as a risk factor for overall survival (AHR =1.30; 95% CI [1.21\u20131.41]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) but a protective factor for cancer-specific mortality (AHR\u2009=\u20090.83; 95% CI [0.72\u20130.94]; <jats:italic>P<\/jats:italic>\u2009=\u20090.004) in comparison with those without prior cancer. The subgroup analysis showed that a prior history of cancer adversely affected overall survival of patients with larynx cancer in most subgroups stratified by timing and types of prior cancer, as well as by different clinicopathologic features.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study indicated an adverse survival impact of a prior history of cancer on patients with larynx cancer. Except for a few particular prior cancer, clinical trials should be considered prudently for laryngeal cancer patients with prior cancers.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07634-2","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T19:04:05Z","timestamp":1606158245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of prior cancer history on the survival of patients with larynx cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Kaiquan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingwang","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"2","key":"7634_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7634_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","volume":"22","author":"JS de Moor","year":"2013","unstructured":"de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561\u201370.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"7634_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271\u201389.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7634_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","volume":"12","author":"MJ Hayat","year":"2007","unstructured":"Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2007;12(1):20\u201337.","journal-title":"Oncologist"},{"issue":"30","key":"7634_CR5","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","volume":"30","author":"ME Wood","year":"2012","unstructured":"Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734\u201345.","journal-title":"J Clin Oncol"},{"key":"7634_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-11-83","volume":"11","author":"DR Youlden","year":"2011","unstructured":"Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011;11:83.","journal-title":"BMC Cancer"},{"issue":"1","key":"7634_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"7634_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","volume":"324","author":"GT Wolf","year":"1991","unstructured":"Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"7634_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/hed.25474","volume":"41","author":"S Strieth","year":"2019","unstructured":"Strieth S, Ernst BP, Both I, Hirth D, Pfisterer LN, K\u00fcnzel J, Eder K. Randomized controlled single-blinded clinical trial of functional voice outcome after vascular targeting KTP laser microsurgery of early laryngeal cancer. Head Neck. 2019;41(4):899\u2013907.","journal-title":"Head Neck"},{"key":"7634_CR10","first-page":"4295960","volume":"2018","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang B, Sun G, Zhang G, Lu L, Liang G. Carbon dioxide laser microsurgery versus low-temperature plasma radiofrequency ablation for T1a Glottic Cancer: a single-blind randomized clinical trial. Biomed Res Int. 2018;2018:4295960.","journal-title":"Biomed Res Int"},{"issue":"2","key":"7634_CR11","first-page":"129","volume":"41","author":"PW Huang","year":"2018","unstructured":"Huang PW, Lin CY, Hsieh CH, Hsu CL, Fan KH, Huang SF, Liao CT, Ng SK, Yen TC, Chang JT, et al. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biom J. 2018;41(2):129\u201336.","journal-title":"Biom J"},{"issue":"4","key":"7634_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdy036","volume":"29","author":"T Kodaira","year":"2018","unstructured":"Kodaira T, Kagami Y, Shibata T, Shikama N, Nishimura Y, Ishikura S, Nakamura K, Saito Y, Matsumoto Y, Teshima T, et al. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan clinical oncology group study (JCOG0701). Ann Oncol. 2018;29(4):992\u20137.","journal-title":"Ann Oncol"},{"key":"7634_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.oraloncology.2019.01.023","volume":"90","author":"YQ Wang","year":"2019","unstructured":"Wang YQ, Lv JW, Tang LL, Du XJ, Chen L, Li WF, Liu X, Guo Y, Lin AH, Mao YP, et al. Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: implications for clinical trial accrual. Oral Oncol. 2019;90:23\u20139.","journal-title":"Oral Oncol"},{"issue":"5","key":"7634_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1740774512456453","volume":"9","author":"M Filion","year":"2012","unstructured":"Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment. Clin Trials (London, England). 2012;9(5):652\u20139.","journal-title":"Clin Trials (London, England)"},{"key":"7634_CR15","doi-asserted-by":"crossref","unstructured":"Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11).","DOI":"10.1093\/jnci\/dju302"},{"key":"7634_CR16","doi-asserted-by":"crossref","unstructured":"Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107(4).","DOI":"10.1093\/jnci\/djv002"},{"issue":"3","key":"7634_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2016.12.024","volume":"144","author":"SR Pierce","year":"2017","unstructured":"Pierce SR, Stine JE, Gehrig PA, Havrilesky LJ, Secord AA, Nakayama J, Snavely AC, Moore DT, Kim KH. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. Gynecol Oncol. 2017;144(3):531\u20135.","journal-title":"Gynecol Oncol"},{"issue":"Suppl 23","key":"7634_CR18","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1002\/cncr.29049","volume":"120","author":"KA Cronin","year":"2014","unstructured":"Cronin KA, Ries LA, Edwards BK. The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Cancer. 2014;120(Suppl 23):3755\u20137.","journal-title":"Cancer"},{"issue":"7","key":"7634_CR19","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.18632\/aging.102984","volume":"12","author":"F Ji","year":"2020","unstructured":"Ji F, Yang CQ, Li XL, Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, et al. Risk of breast cancer-related death in women with a prior cancer. Aging. 2020;12(7):5894\u2013906.","journal-title":"Aging"},{"key":"7634_CR20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.lungcan.2004.07.998","volume":"45 Suppl 2","author":"AJ Sasco","year":"2004","unstructured":"Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer (Amsterdam, Netherlands). 2004;45 Suppl 2:S3\u20139.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"27","key":"7634_CR21","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1200\/JCO.2007.15.3726","volume":"26","author":"J Lemieux","year":"2008","unstructured":"Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T, Camden S, Speers CH. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol. 2008;26(27):4458\u201365.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7634_CR22","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdq078","volume":"21","author":"RK Pandurengan","year":"2010","unstructured":"Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010;21(10):2107\u201311.","journal-title":"Ann Oncol"},{"issue":"3","key":"7634_CR23","first-page":"180","volume":"76","author":"PP Varty","year":"1994","unstructured":"Varty PP, Delrio P, Boulos PB. Survival in colorectal carcinoma associated with previous extracolonic cancer. Ann R Coll Surg Engl. 1994;76(3):180\u20134.","journal-title":"Ann R Coll Surg Engl"},{"key":"7634_CR24","doi-asserted-by":"crossref","unstructured":"Al-Husseini MJ, Saad AM, Turk T, Tabash MA, Abdel-Rahman O. Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.\u00a0J Gastrointest Cancer. 2019;50(4):794\u2013800.","DOI":"10.1007\/s12029-018-0158-4"},{"issue":"2","key":"7634_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10428190802645061","volume":"50","author":"D Pulte","year":"2009","unstructured":"Pulte D, Gondos A, Brenner H. Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leukemia Lymphoma. 2009;50(2):179\u201386.","journal-title":"Leukemia Lymphoma"},{"key":"7634_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lungcan.2016.05.029","volume":"98","author":"AL Laccetti","year":"2016","unstructured":"Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer (Amsterdam, Netherlands). 2016;98:106\u201313.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"3","key":"7634_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2017.02.002","volume":"3","author":"BC \u00d6zdemir","year":"2017","unstructured":"\u00d6zdemir BC, Dotto GP. Racial differences in Cancer susceptibility and survival: more than the color of the skin? Trends Cancer. 2017;3(3):181\u201397.","journal-title":"Trends Cancer"},{"issue":"4","key":"7634_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21340","volume":"66","author":"CE DeSantis","year":"2016","unstructured":"DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290\u2013308.","journal-title":"CA Cancer J Clin"},{"issue":"31","key":"7634_CR29","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","volume":"31","author":"AA Aizer","year":"2013","unstructured":"Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869\u201376.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7634_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10549-005-3702-4","volume":"93","author":"C Osborne","year":"2005","unstructured":"Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat. 2005;93(1):41\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7634_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.urolonc.2008.04.016","volume":"27","author":"JL Nelles","year":"2009","unstructured":"Nelles JL, Joseph SA, Konety BR. The impact of marriage on bladder cancer mortality. Urol Oncol. 2009;27(3):263\u20137.","journal-title":"Urol Oncol"},{"issue":"21","key":"7634_CR32","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1001\/jama.1987.03400210067027","volume":"258","author":"JS Goodwin","year":"1987","unstructured":"Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. Jama. 1987;258(21):3125\u201330.","journal-title":"Jama"},{"issue":"10","key":"7634_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJM198803103181006","volume":"318","author":"ER Greenberg","year":"1988","unstructured":"Greenberg ER, Chute CG, Stukel T, Baron JA, Freeman DH, Yates J, Korson R. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med. 1988;318(10):612\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"7634_CR34","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1634\/theoncologist.12-12-1456","volume":"12","author":"A Jatoi","year":"2007","unstructured":"Jatoi A, Novotny P, Cassivi S, Clark MM, Midthun D, Patten CA, Sloan J, Yang P. Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the mayo clinic lung cancer cohort. Oncologist. 2007;12(12):1456\u201363.","journal-title":"Oncologist"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07634-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T19:09:33Z","timestamp":1606158573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07634-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7634"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07634-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses of human data conducted in this study were approved by the Institutional Review Board of The First Affiliated Hospital of Wenzhou Medical University and in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was exempted because of the retrospective nature of this study. All authors signed authorization forms and received permission from SEER to access and use the dataset.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1137"}}